Human parvovirus PARV4 in plasma pools of Chinese origin

Vox Sanguinis

Volumn 103, Issue 3, 2012, Pages 183-185

  Ma, Y Y ^a   Guo, Y ^a   Zhao, X ^a   Wang, Z ^a   Lv, M M ^a   Yan, Q P ^a   Zhang, J G ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Human parvovirus 4; Real time quantitative PCR; Source plasma pools

Indexed keywords

VIRUS DNA;

ARTICLE; BLOOD ANALYSIS; CHINA; CHINESE; GENE AMPLIFICATION; GENE DOSAGE; HUMAN PARVOVIRUS 4; NUCLEOTIDE SEQUENCE; PARECHOVIRUS; PARVOVIRUS INFECTION; PLASMA; PLASMAPHERESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS DETECTION;

ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84866453463     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01605.x     Document Type: Article

References (12)

1. Brown KE: The expanding range of parvoviruses which infect humans. Rev Med Virol 2010; 20:231-244
2. Azzi A, Morfini M, Mannucci PM: The transfusion associated transmission of parvovirus B19. Transfus Med Rev 1999; 13:194-204
3. Servant-Delmas A, Laperche S, Mercier M, et al.: Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion 2009; 49:1771-1773
4. Jones MS, Kapoor A, Lukashov VV, et al.: New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79:8230-8236
5. Fryer JF, Kapoor A, Minor PD, et al.: Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006; 12:151-154
6. Fryer JF, Delwart E, Hecht FM, et al.: Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007; 47:1054-1061
7. Plasma Protein Therapeutics Association (PPTA). Voluntary Standards Parvovirus B19. August 2003.
8. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry: Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma-Derived Products. Rockville, U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2009.
9. Simmons R, Sharp C, Sims S, et al.: High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo. J Infect Dis 2011; 203:1378-1387
10. Yang SJ, Hung CC, Chang SY, et al.: Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection. J Clin Virol 2011; 51:64-67
11. Touinssi M, Reynaud-Gaubert M, Gomez C, et al.: Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts. J Med Virol 2011; 83:717-720
12. Schneider B, Fryer JF, Reber U, et al.: Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol 2008; 80:345-351